
Opinion|Videos|March 7, 2025
KarMMa-3 Trial: Additional Insights From Ide-Cel in RRMM
Panelists discuss how detailed analyses from KarMMa-3 reveal key insights about ide-cel’s performance across patient subgroups, timing of responses, durability of remissions, and management of adverse effects in relapsed/refractory multiple myeloma (RRMM).
Episodes in this series






































